MASLD and MASH: Steatotic liver disease joins the deadly quartet.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 42680525.
- Also identified by DOI 10.3949/ccjm.93a.25117.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to insulin resistance and cardiometabolic disorders. This review synthesizes current information on the epidemiology, pathophysiology, and treatment of MASLD and its progressive form, metabolic dysfunction- associated steatohepatitis (MASH), underscoring how to integrate established metabolic care with emerging treatments to address the growing MASLD burden.
Medical subject headings
- Fatty Liver